• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

镰状细胞病年轻患者接受医疗过渡后使用羟脲的情况。

Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance.

机构信息

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill.

Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, The University of Memphis, Memphis, Tennessee.

出版信息

JAMA Netw Open. 2021 Oct 1;4(10):e2128971. doi: 10.1001/jamanetworkopen.2021.28971.

DOI:10.1001/jamanetworkopen.2021.28971
PMID:34643722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8515209/
Abstract

This cohort study examines whether hydroxyurea use changes in young adults with sickle cell disease who are transitioning from pediatric to adult health care.

摘要

这项队列研究旨在探讨在从儿科到成人保健过渡的镰状细胞病年轻患者中，羟脲的使用是否会发生变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbd0/8515209/97efd558b0be/jamanetwopen-e2128971-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbd0/8515209/97efd558b0be/jamanetwopen-e2128971-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbd0/8515209/97efd558b0be/jamanetwopen-e2128971-g001.jpg

相似文献

1
Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance.镰状细胞病年轻患者接受医疗过渡后使用羟脲的情况。
JAMA Netw Open. 2021 Oct 1;4(10):e2128971. doi: 10.1001/jamanetworkopen.2021.28971.
2
Hydroxyurea use in patients with sickle cell disease in a Medicaid population.医疗补助计划人群中镰状细胞病患者使用羟基脲的情况。
Am J Hematol. 2011 Oct;86(10):888-90. doi: 10.1002/ajh.22134. Epub 2011 Aug 22.
3
Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.在马拉维的卡穆祖中央医院，镰状细胞病患儿使用羟基脲的情况日益增多。
Blood Adv. 2018 Nov 30;2(Suppl 1):30-32. doi: 10.1182/bloodadvances.2018GS110347.
4
Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries.中美洲和加勒比国家镰状细胞贫血患儿的羟基脲治疗
Pediatr Blood Cancer. 2006 Jul;47(1):111-2. doi: 10.1002/pbc.20823.
5
When should hydroxyurea be used for children with sickle cell disease?镰状细胞病患儿何时应使用羟基脲？
Pediatrics. 2008 Dec;122(6):1365-6. doi: 10.1542/peds.2008-1058.
6
Hydroxyurea in sickle cell disease.羟基脲用于镰状细胞病
MCN Am J Matern Child Nurs. 1996 Jul-Aug;21(4):210. doi: 10.1097/00005721-199607000-00029.
7
Accidental hydroxyurea overdosage in a child with sickle cell anemia: An African experience.一名镰状细胞贫血患儿意外过量服用羟基脲：非洲的经验。
Pediatr Blood Cancer. 2020 Oct;67(10):e28632. doi: 10.1002/pbc.28632. Epub 2020 Aug 2.
8
High hydroxyurea usage in sickle cell anemia regardless of patient demographics.高剂量羟基脲在镰状细胞贫血中的应用，与患者人口统计学特征无关。
Pediatr Blood Cancer. 2024 Feb;71(2):e30728. doi: 10.1002/pbc.30728. Epub 2023 Dec 9.
9
Hydroxyurea Initiation Among Children With Sickle Cell Anemia.镰状细胞贫血患儿开始使用羟基脲治疗的情况。
Clin Pediatr (Phila). 2019 Nov;58(13):1394-1400. doi: 10.1177/0009922819850476. Epub 2019 May 21.
10
Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea.羟基脲治疗镰状细胞贫血患儿脑动脉狭窄的缓解情况
Am J Hematol. 2010 Feb;85(2):135-7. doi: 10.1002/ajh.21596.

引用本文的文献

1
A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.一项多层次的移动医疗干预措施可提高镰状细胞病患者对羟基脲的依从性。
Blood Adv. 2023 Dec 12;7(23):7190-7201. doi: 10.1182/bloodadvances.2023010670.
2
Burden of Aging: Health Outcomes Among Adolescents and Young Adults With Sickle Cell Disease.衰老负担：镰状细胞病青少年和青年的健康结局
Hemasphere. 2023 Jul 13;7(8):e930. doi: 10.1097/HS9.0000000000000930. eCollection 2023 Aug.
3
Barriers to medication adherence in sickle cell disease: A comprehensive theory-based evaluation using the COM-B model.

本文引用的文献

1
Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.羟脲在参加医疗补助计划的镰状细胞病儿童中的应用。
Pediatrics. 2019 Jul;144(1). doi: 10.1542/peds.2018-3285.
2
Hydroxyurea for children with sickle cell anemia: Prescribe it early and often.给镰状细胞贫血患儿使用羟基脲：尽早且频繁给药。
Pediatr Blood Cancer. 2019 Aug;66(8):e27778. doi: 10.1002/pbc.27778. Epub 2019 Apr 30.
3
Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study.镰状细胞病患者住院和再入院的风险因素：一项美国调查研究的结果
镰状细胞病患者药物依从性的障碍：使用COM-B模型进行基于理论的综合评估
Pediatr Blood Cancer. 2023 May 27:e30440. doi: 10.1002/pbc.30440.
4
Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease.评估一项多层次移动健康研究的实施情况，以提高镰状细胞病患者对羟基脲的使用率。
Front Health Serv. 2023 Jan 20;2:1024541. doi: 10.3389/frhs.2022.1024541. eCollection 2022.
5
The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease.使用美国食品药品监督管理局（FDA）批准的药物预防镰状细胞病的血管闭塞性事件。
Blood Adv. 2023 Jul 11;7(13):3114-3116. doi: 10.1182/bloodadvances.2022008965.
Hematology. 2019 Dec;24(1):189-198. doi: 10.1080/16078454.2018.1549801.
4
Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.羟基脲疗法用于镰状细胞病患儿：描述护理人员如何做出这一决定。
BMC Res Notes. 2015 Aug 25;8:372. doi: 10.1186/s13104-015-1344-0.
5
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.羟基脲在降低小儿镰状细胞病疼痛发作和住院频率方面的成本效益。
Am J Hematol. 2010 Oct;85(10):795-7. doi: 10.1002/ajh.21772.
6
Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature.孕期使用羟基脲：镰状细胞病病例报告及文献综述
Am J Hematol. 1999 Feb;60(2):148-50. doi: 10.1002/(sici)1096-8652(199902)60:2<148::aid-ajh12>3.0.co;2-i.